Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

AGN GILD PFE REGN LBIO

Trades from $3

For Immediate Release

Chicago, IL – November 04, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Allergan plc (NYSE: (AGN - Free Report) -Free Report ), Gilead Sciences Inc. (NASDAQ: (GILD - Free Report) -Free Report ), Pfizer Inc. (NYSE: (PFE - Free Report) -Free Report ), Regeneron Pharmaceuticals, Inc. (NASDAQ: (REGN - Free Report) -Free Report ) and Lion Biotechnologies, Inc. (NASDAQ: (LBIO - Free Report) -Free Report )

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

Drug Stocks to Watch for Earnings on Friday

The bulk of the Q3 earnings season is over, with 364 S&P 500 members (as of Nov 2) – accounting for 72.6% of the index’s total market capitalization – having already reported results, according to the latest Earnings Outlook.

While total earnings for these index members were up 1.6% from the year-ago quarter, revenues were also up 1.6% year over year. The beat ratio was 72.3% for earnings and 54.7% for revenues.

Notably, the ongoing reporting cycle is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. However, though the third-quarter reporting cycle saw numerous positive surprises and stability in current-quarter (Q4 2016) estimates in the beginning, these two attributes have started losing ground this week. Positive surprises, particularly on the revenue side, have become harder to come by and Q4 estimates are moving down.

This change was reflected in the results of pharmaceutical companies as well. Though quite a few of the large-cap pharma companies posted better-than-expected third-quarter results last week, three large pharma companies that have reported so far this week – Allergan plc’s (NYSE: (AGN - Free Report) -Free Report ), Gilead Sciences Inc. (NASDAQ: (GILD - Free Report) -Free Report ) and Pfizer Inc. (NYSE: (PFE - Free Report) -Free Report ) – announced softer-than-expected Q3 results. While Allergan and Pfizer missed estimates for both earnings and sales, Gilead managed to beat sales expectations marginally but missed earnings estimates.

Two more companies from the healthcare sector are set to report their third-quarter results on Nov 4. Let's see how things are shaping up for their respective announcements.

Regeneron Pharmaceuticals, Inc. ( NASDAQ: (REGN - Free Report) -Free Report )

Regeneron posted a positive surprise of 21.97% last reported. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed the same twice. Overall, the company has recorded an average negative earnings surprise of 2.04%.

Regeneron’s key growth driver, Eylea, should continue to perform well in the third quarter of 2016 and contribute meaningfully to the top line. Apart from Eylea, investor focus will remain on the performance of the PCSK9 inhibitor, Praluent. (Read More: Regeneron Q3 Earnings: Will the Stock Surprise? ).

The Zacks Consensus Estimate for the quarter is pegged at $2.27 per share. The company has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.

Lion Biotechnologies, Inc. ( NASDAQ: (LBIO - Free Report) -Free Report )

Last quarter, the company delivered a negative earnings surprise of 21.05%. Lion Biotechnologies had a mixed track record over the last four quarters. The company surpassed expectations twice, missed once and delivered in-line results in the other quarter, with the average positive earnings surprise being 9.52%.

The Zacks Consensus Estimate for the quarter is pegged at a loss of 18 cents per share. The company has an Earnings ESP of 0.00% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

Confidential from Zacks

This week, Zacks researchers have named 7 other stocks that look to break out even sooner than today's Bull of the Day. You can see these time-sensitive tickers free, and access additional trades that are not available to the public. Simply click here>>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on AGN - FREE

Get the full Report on GILD - FREE

Get the full Report on PFE - FREE

Get the full Report on REGN - FREE

Get the full Report on LBIO - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.